⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL964382 | 0.70 | — | — | |
| SCHEMBL11449217 | 0.62 | — | — | |
| SCHEMBL3959729 | 0.61 | PLAU (0.42) | — | |
| SCHEMBL1591924 | 0.55 | PDE7A (0.31) | — | |
| SCHEMBL630051 | 0.51 | — | — | |
| SCHEMBL596987 | 0.50 | — | — | |
| SCHEMBL5380749 | 0.50 | — | — | |
| SCHEMBL5892770 | 0.50 | — | — | |
| SCHEMBL22010631 | 0.50 | — | — | |
| SCHEMBL183955 | 0.49 | CRBN (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 245 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2448926-A1 | FLAVIN DERIVATIVES | Biorelix, Inc. (US) | 2012-05-09 | — | — | EP | claimed |
| US-8084448-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-12-27 | — | — | US | claimed |
| EP-2185567-B1 | SUBSTITUTED BICYCLOLACTAM COMPOUNDS | PFIZER PROD INC (US) | 2011-03-23 | — | — | EP | claimed |
| WO-2011008247-A1 | FLAVIN DERIVATIVES | BIORELIX, INC. (US) | 2011-01-20 | — | — | WO | claimed |
| JP-2000511883-A | — | — | 2000-09-12 | — | — | JP | claimed |
| US-5972978-A | FOR USE IN TREATMENT OF HUMAN AND ANIMAL DISORDERS, USE FOR PURIFICATION OF PROTEINS OR GLYCOPROTEINS, USE IN DIAGNOSIS | NOVO NORDISK A/S (DK) | 1999-10-26 | — | — | US | claimed |
| WO-1997040017-A2 | MODULATORS OF MOLECULES WITH PHOSPHOTYROSINE RECOGNITION UNITS | NOVO NORDISK A/S (DK) | 1997-10-30 | — | — | WO | claimed |
| US-20230390410-A1 | COMPOUNDS AND COMPOSITIONS FOR IMMUNOTHERAPY | BIRDIE BIOPHARMACEUTICALS INC (KY) | 2023-12-07 | — | — | US | disclosed |
| US-11786604-B2 | Compounds and compositions for treating HER2 positive tumors | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2023-10-17 | — | — | US | disclosed |
| US-11702476-B2 | Anti-EGFR combinations for treating tumors | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2023-07-18 | — | — | US | disclosed |
| US-20230192684-A1 | SUBSTITUTED INDOLES WITH INHIBITORY ACTIVITY | UNIV OF PITTSBURGH OF THE COMMONWEALTH SYSTEM OF HIGHER HIGHER EDUCATION (US) | 2023-06-22 | — | — | US | disclosed |
| EP-3166640-B1 | COMBINATION THERAPY COMPOSITIONS AND METHODS FOR TREATING CANCERS | BIRDIE BIOPHARMACEUTICALS INC (KY) | 2023-06-14 | — | — | EP | disclosed |
| US-11633494-B2 | Compounds and compositions for immunotherapy | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2023-04-25 | — | — | US | disclosed |
| WO-2005080346-A1 | SUBSTITUTED AZOLE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE | TRANSTECH PHARMA, INC. (US) | 2005-09-01 | — | — | WO | disclosed |
| US-20050187277-A1 | Substituted azole derivatives, compositions, and methods of use | TRANSTECH PHARMA, INC. | 2005-08-25 | — | — | US | disclosed |
| EP-1565463-A1 | IMIDAZO[1,5A]PYRIDINE DERIVATIVES AND METHODS FOR TREATING ALDOSTERONE MEDIATED DISEASES | Novartis AG (CH) | 2005-08-24 | — | — | EP | disclosed |
| US-20050090502-A1 | Protein tyrosine phosphatase 1B inhibitors alone or incombination with other antidiabetic, antilipemic, anticholesterol or hypotensive agents | NOVARTIS AG (CH) | 2005-04-28 | — | — | US | disclosed |
| US-20050049310-A1 | Aryl and heteroaryl compounds, compositions and methods of use | VTVX HOLDINGS I LLC | 2005-03-03 | — | — | US | disclosed |
| WO-2004046145-A1 | IMIDAZO[1, 5A]PYRIDINE DERIVATIVES AND METHODS FOR TREATING ALDOSTERONE MEDIATED DISEASES | NOVARTIS AG (CH) | 2004-06-03 | — | — | WO | disclosed |
| US-20040023974-A1 | Cyclic sulfamide derivatives and methods of use | COPPOLA GARY MARK | 2004-02-05 | — | — | US | disclosed |